Eyepoint Pharmaceuticals Stock News

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target upped by Cowen from $25.00 to $35.00 in a research note published on Monday, The Fly reports. They currently have an outperform rating on the stock. Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a buy rating and set a $24.00 target []

HC Wainwright reissued their buy rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) in a research report report published on Monday, Price Targets.com reports. The firm currently has a $24.00 target price on the stock, up from their previous target price of $15.00. Separately, Zacks Investment Research lowered shares of EyePoint Pharmaceuticals from a hold rating […]

The eyecare specialist has good momentum behind it as it prices a new round of capital raising.

The shares of Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) increased by over 30% during intraday trading today. This is why it happened.

Vanguard Group Inc. boosted its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 20.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,086,329 shares of the companys stock after acquiring an additional 181,890 shares during the quarter. Vanguard Group []

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has priced an underwritten public offering of 4.03 million at $13.75 per share and pre-funded warrants to purchase up to an aggregate of 3.27 million sha

EyePoint Pharmaceuticals (EYPT) stock is heading higher on Monday thanks to interim results from a Phase 1 clinical trial. The post EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investo

The stock price of Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) increased by over 35% pre-market today. This is why it happened.

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.40% and -5.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live

– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD –